Trevi Therapeutics
Stock Forecast, Prediction & Price Target
Trevi Therapeutics Financial Estimates
Trevi Therapeutics Revenue Estimates
Trevi Therapeutics EBITDA Estimates
Trevi Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $1.18M Low: $1.18M High: $1.18M avg. 0% | Avg: $12.23M Low: $12.23M High: $12.23M avg. 936.45% | Avg: $113.25M Low: $113.25M High: $113.25M avg. 826.03% |
Net Income
% change YoY
| $-33.94M N/A | $-29.15M 14.10% | $-29.06M 0.29% | Avg: $-53.5M Low: $-61.40M High: $-37.63M avg. -84.07% | Avg: $-79.1M Low: $-87.14M High: $-49.51M avg. -47.85% | Avg: $-70.90M Low: $-70.90M High: $-70.90M avg. 10.35% | Avg: $-12.28M Low: $-12.28M High: $-12.28M avg. 82.68% |
EBITDA
% change YoY
| $-32.79M N/A | $-29.90M 8.79% | $-33.8M -13.01% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.49 N/A | -$0.45 69.79% | -$0.29 35.55% | Avg: -$0.46 Low: -$0.62 High: -$0.38 avg. -58.62% | Avg: -$0.68 Low: -$0.88 High: -$0.5 avg. -48.54% | Avg: -$0.72 Low: -$0.72 High: -$0.72 avg. -4.78% | Avg: -$0.12 Low: -$0.12 High: -$0.12 avg. 82.68% |
Operating Expenses
% change YoY
| $32.47M N/A | $29.90M -7.91% | $33.92M 13.42% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Trevi Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -9.72% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -61.40M, average is -53.5M and high is -37.63M.
What is Trevi Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 440.62% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Trevi Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.31% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.62, average is -$0.46 and high is $-0.38.
What is the best performing analyst?
In the last twelve months analysts have been covering Trevi Therapeutics stock. The most successful analyst is Oren Livnat.